Explore our product offering by market:
We are a world leader in pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications.

Human pharmaceuticals
We specialise in developing the highest quality and purest grades of pharmaceutical excipients, lipids and vaccine adjuvants to help you formulate seamlessly and drive your products to market. We tailor excipient purity to your needs. We are committed to product quality, regulatory excellence, and supply chain security. We have worked with many pharma companies to bring COVID-19 vaccines and treatments to market faster, using our adjuvant and Super Refined™ excipients. While continuing to invest in expanding our portfolio and manufacturing footprint globally, quality is at the forefront of our plans.

Veterinary health
To serve the growing veterinary health market, we develop and commercialise a wide range of specialty excipients which are used to enhance the delivery, efficacy, and stability of actives in livestock and companion animal health products. Our broad portfolio also comprises adjuvants for the important veterinary vaccine market and extends further to omega-3 essential fatty acids for pet food products. We collaborate with your formulation scientists to produce safer, more efficient, and highly specialised products that are used across a variety of marketed veterinary dosage forms. We strive to offer innovative solutions to meet the challenges formulators, veterinarians and livestock producers face every day.
Explore recent blogs:

Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4F9521E2A9CDAB872D1AA12B9BA9F4EB)
From Lab to Patient: Optimising Oncology Formulations with Purified Excipients
In 2024, we hosted a live webinar exploring the impact of our Super RefinedTM excipients on various chemotherapeutic formulations. This blog will explore some of the key learnings from the webinar.
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F330DFD631D5F6E81578038D37E005ED)
Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to...